Targeting New Pathways for the Treatment of an Aggressive Form of B-Cell Lymphoma

lecBy Leandro Cerchietti, MD

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and fast-growing lymphoma that is the most common form of non-Hodgkin lymphoma in the United States. Nearly 1/3 of DLBCL patients experience relapse. The outcome can be worse for patients with DLBCL that harbor activation of multiple oncogenes. An oncogene is a gene that can “hit” a cell to transform it into a cancer cell. Some cells are “hit” with more than one oncogene. When hit by two or three oncogenes they transform into a very aggressive lymphoma called double-hit and triple-hit lymphomas (DH/TH). These DH/TH are largely insensitive to combinatorial chemotherapy and are more frequently found in the elderly. To grapple with the complexities of treatment of DH/TH lymphomas, alternate pathways for the development of future treatments must be found by researchers.

The three oncogenes that could drive these lymphomas are MYC, BCL2 and BCL6, but it is not know whether all three work simultaneously. In a paper recently published in OncoTarget, researchers from my lab at Weill Cornell Medicine found that DLBCL cells that survive BCL6 targeted therapy induce a phenomenon of “oncogene-addiction switching” and super activate one of the other oncogenes, preferentially BCL2. The activation of BCL2 by the anti BCL6 therapy allows lymphoma cell to survive this targeted treatment. My team found that to be effective in killing lymphoma cells a therapy should inhibit both the BCL6 and BCL2 oncogenes.

This phenomenon occurs because these three oncogenes share the regulation of common pathways responsible for the survival of DLBCL. If one oncogene is targeted, the others can take the leading role. In the case of BCL6, specific targeting of BCL6 releases BCL2 inducing on-target feedback resistance to this therapeutic strategy. However, this “oncogene-addiction switching” mechanism can be harnessed to develop rational combinatorial therapies for DLBCL.

An alternative strategy to target DH/TH DLBCLs could be to simultaneously dismantle all three oncogenic networks. In a separate paper recently published in Blood, researchers from my lab and the University of Montreal found another potential therapeutic pathway for the treatment of these aggressive DLBCLs. They found that the protein Hsp90 binds to and maintains activity in eIF4E a protein that controls MYC, BCL6, and BCL2 networks. Inhibition of eIF4E using the antiviral drug Ribavirin decreases simultaneously MYC, BCL6, and BCL2 avoiding “oncogene-addiction switching” and inducing regression of DH/TH DLBCLs. The researchers used a novel pre-clinical model of lymphoma called “patient-derived tumorgrafts”, that are mouse models faithfully resembling the complexity of human lymphomas.

They also found that DH/TH could be targeted with Hsp90 inhibitors. Still targeting Hsp90 activity has met with limited success in the past due to the counter regulatory elevation of Hsp70, which induces resistance to Hsp90 inhibitors. However, researchers were able to identify Hsp70 as a target for eIF4E. Accordingly the combination of eIF4E and Hsp90 inhibitors should result in a potential new pathway for the development of new treatments for DLBCL, an approach WCM clinicians will test in future clinical trials.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s